Healthcare provider profile · identity verified

Vineet Puri, MD

Internal Medicine · DOVER, DE · NPI 1548215981

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	337	109
Amlodipine Besylate	Amlodipine Besylate	189	63
Levothyroxine Sodium	Levothyroxine Sodium	163	49
Lisinopril	Lisinopril	156	48
Omeprazole	Omeprazole	112	34
Hydrochlorothiazide	Hydrochlorothiazide	108	34
Pantoprazole Sodium	Pantoprazole Sodium	104	23
Albuterol Sulfate Hfa	Albuterol Sulfate	98	23
Metformin Hcl	Metformin Hcl	90	33
Metoprolol Succinate	Metoprolol Succinate	90	28
Losartan Potassium	Losartan Potassium	85	26
Gabapentin	Gabapentin	82	24
Rosuvastatin Calcium	Rosuvastatin Calcium	65	23
Alprazolam	Alprazolam	64	18
Fluoxetine Hcl	Fluoxetine Hcl	62	18
Carvedilol	Carvedilol	61	17
Simvastatin	Simvastatin	56	19
Metoprolol Tartrate	Metoprolol Tartrate	55	16
Ozempic	Semaglutide	51	suppressed
Jardiance	Empagliflozin	50	14
Furosemide	Furosemide	46	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	45	13
Ezetimibe	Ezetimibe	41	11
Glimepiride	Glimepiride	40	suppressed
Sertraline Hcl	Sertraline Hcl	40	suppressed
Tradjenta	Linagliptin	39	suppressed
Allopurinol	Allopurinol	38	12
Citalopram Hbr	Citalopram Hydrobromide	38	suppressed
Januvia	Sitagliptin Phosphate	38	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	12
Fluticasone Propionate	Fluticasone Propionate	33	12
Ropinirole Hcl	Ropinirole Hcl	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Farxiga	Dapagliflozin Propanediol	32	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	32	suppressed
Donepezil Hcl	Donepezil Hcl	30	suppressed
Eliquis	Apixaban	30	suppressed
Glipizide Er	Glipizide	28	suppressed
Tramadol Hcl	Tramadol Hcl	28	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	27	suppressed
Alendronate Sodium	Alendronate Sodium	26	suppressed
Metformin Hcl Er	Metformin Hcl	24	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	24	suppressed
Famotidine	Famotidine	23	suppressed
Meloxicam	Meloxicam	22	suppressed
Amoxicillin	Amoxicillin	21	19
Azithromycin	Azithromycin	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Atenolol	Atenolol	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Meclizine Hcl	Meclizine Hcl	20	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Naproxen	Naproxen	16	suppressed
Prednisone	Prednisone	16	13
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	15	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	12
Trulicity	Dulaglutide	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Fenofibrate	Fenofibrate,micronized	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Valsartan	Valsartan	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error